Expert Interview
Examining Structure Therapeutics' GLP-1 candidate GSBR-1290 and the results from its phase 1b clinical trial in type 2 diabetes.
Ticker(s): GPCRInstitution: University of Arkansas Medical Services Health
- Director of the diabetes program at UAMS Health
- Clinical interests include type 1 diabetes, type 2 diabetes, Diabetes management with exercise, insulin pumps, closed-look insulin pump systems, and continuous glucose monitoring systems
- Manages about 600 patients with type 2 diabetes and is familiar with Brenzavvy via the published clinical trials
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
